Radiopharm Theranostics Limited (RADX), Tuesday announced the second interim data from its U.S. Phase 2b clinical imaging trial of RAD 101, a novel, small-molecule imaging agent targeting fatty acid synthase, in brain metastases.
The data showed that 90 percent of the participants dosed with RAD101 achieved concordance between PET imaging and MRI, showing significant and selective tumor uptake in the brain metastases.
Additionally, the first five patients with evaluable six-month follow-up and/or biopsy data show a positive trend for sensitivity and specificity.
Looking ahead, the company expects to the final data readout from the full 30-patient study by June.
In the pre-market hours, RADX is trading at $5.00, up 7.76 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.